Avastin (bevacizumab) / Roche  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

170 Trials

   Remove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Avastin (bevacizumab) / Roche
ACTRN12622001514796: KARPOS - A Phase 1, Single-Centre, Non-randomised, Open-labelled, Escalating Dose Study of Autologous GD2-Specific Chimeric Antigen Receptor-expressing Peripheral Blood T cells in Patients with Recurrent GD2-positive Glioblastoma Multiforme

Recruiting
N/A
18
 
Royal Adelaide Hospital, Neurosurgical Research Foundation
Glioblastoma Multiforme
 
 
ACTRN12622000675729: Leveraging Chimeric Antigen Receptor-Expressing T Cells for Children with Diffuse Midline Glioma

Recruiting
N/A
18
 
Sydney Children's Hospitals Network, Levi's Project, Australian Philanthropic Services, Cancer Institute NSW, Medical Research Future Fund, Australian Government Department of Health, Cure Cancer Australia Foundation
Central Nervous System Tumour, Diffuse Midline Glioma, High Grade Glioma, Diffuse Intrinsic Pontine Glioma
 
 
ACTRN12624000110583: SOCRATES PILOT: Standard of Care Randomised Treatment Evaluation Studies

Recruiting
N/A
200
 
The University of Sydney, National Health Medical Research Council
Cancer, Cardio Vascular Disease
 
 
ChiCTR-TRC-09000697: Effects of Different Dosages of intravitreal Bevacizumab (Avastin) for Neovascular Age-related Macular Degeneration: A Randomized Controlled Trial

Completed
N/A
50
 
1.25mg intravitreal bevacizumab at monthly interval 3 to 6 months versus 2.5mg intravitreal bevacizumab
NA; Level of the institution:, Department of Ophthalmology and Visual Sciences
Neovascular age-related macular degeneration
 
 
ChiCTR-TRC-09000698: Effect of Different Dosages of Intravitreal Bevacizumab (Avastin) in the Treatment of Diabetic Macular Edema: A Randomized Controlled Trial

Completed
N/A
52
 
1.25mg intravitreal bevacizumab at monthly 3 months versus 2.5mg intravitreal bevacizumab
NA; Level of the institution:, Department of Ophthalmology and Visual Sciences
Diabetic Macular Edema
 
 
ChiCTR-TRC-09000696: The Safety and Efficacy of Combined Subtenon Triamcinolone Acetonide, Intravitreal Bevacizumab and Grid Laser Photocoagulation for Refractory Diabetic Macular Edema - A Pilot Study

Completed
N/A
30
 
Subtenon triamcinolone, intravitreal bevacizumab injections and macular photocoagulation 2 months
NA; None, Department of Ophthalmology and Visual Sciences The Chinese University of Hong Kong
Refractory diabetic macular edema
 
 
NCT00372866: Chemotherapy and Bevacizumab in Treating Women With Invasive Breast Cancer

Recruiting
N/A
30
US
bevacizumab, filgrastim, pegfilgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, adjuvant therapy
Premiere Oncology
Breast Cancer
 
 
NCT01301547: Bevacizumab and Polyethyleneglycol-7-Ethyl-10-Hydroxycamptothecin in Treating Patients With Refractory Solid Tumors

Recruiting
N/A
20
US
bevacizumab, polyethyleneglycol-7-ethyl-10-hydroxycamptothecin, protein expression analysis, laboratory biomarker analysis
National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
09/11
 
ChiCTR-TRC-08000711: Needling with adjunctive intravitreal injection of bevacizumab (avastin). A preliminary study.

Completed
N/A
30
 
Needling with intravitreal injection of Bevacizumab (Avastin) vs No control or comparative treatment for this study for 10 to 15min
NA; Level of the institution:, Departmental funding from DOVS, CUHK (for the drug bevacizumab (avastin))
Glaucoma
 
 
ChiCTR-ONC-08000714: Intravitreal injection of Bevacizumab (Avastin) as an adjunctive therapy of pterygium surgery to prevent recurrence: A pilot study

Completed
N/A
50
 
Intravitreal injection of Bevacizumab (Avastin?) after surgical excision of pterygium immediately
NA; Level of the institution:, NA
pterygium
 
 
ChiCTR-TRC-10000973: Study of exogenous endothelial progenitor cell in enhancing the antitumor effect of bevacizumab for recurrent ovarian cancer

Completed
N/A
20
 
exogenous endothelial progenitor cell plus Bevacizumab ;Bevacizumab alone
Third military medical university; Third military medical university, The clinical research fund of third military medical university
recurrent ovarian cancer
 
 
ChiCTR-ONRC-12002722: The tumors biological treatment of non-surgical hepatocellular carcinoma

Completed
N/A
180
 
Traditional chemotherapy ;Traditional chemotherapy+Bevacizumab ;Traditional chemotherapy+CIK ;chemotherapy+Bevacizumab+CIK ;Traditional chemotherapy+Megestrol ;Traditional chemotherapy+Bevacizumab+CIK+Megestrol
First Affiliated Hospital, Shenzhen University, Futian District, Shenzhen, Guangdong Province; Level of the institution:, Shenzhen Innovation Committee
Inoperable hepatocellular carcinoma
 
 
ChiCTR1800018768: Evaluation Of The Efficacy And Safety Of Intrapleural Injection Of Bevacizumab Treatment Of Malignant Pleural Effusion Caused By Lung Adenocarcinoma

Recruiting
N/A
60
 
thoracic perfusion therapy ;thoracic perfusion therapy
The Affiliated Hospital of Inner Mongolia Medical University; The Affiliated Hospital of Inner Mongolia Medical University, The Affiliated Hospital of Inner Mongolia Medical University
Malignant Pleural Effusion Caused By Lung Adenocarcinoma
 
 
ChiCTR-IOD-16009803: The effect of ultra low dose of bevacizumab for brain radiation necrosis of the brain

Recruiting
N/A
30
 
5mg/kg Bevacizumab ;1 mg/kg Bevacizumab
Tianjin Medical University Cancer Institute and Hospital; Tianjin Medical University Cancer Institute and Hospital, Wu Jieping fund
Brain radiation necrosis
 
 
NCT06559488: IVB for Post-vitrectomy Hemorrhage in Diabetic Eyes

Completed
N/A
18
RoW
Bevacizumab Injection [Avastin], Pars Plana Vitrectomy
Universitas Padjadjaran, Cicendo Eye Hospital
Diabetic Retinopathy, Vitreous Hemorrhage
03/19
03/19
ChiCTR-OOC-15006173: Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas

Not yet recruiting
N/A
30
 
ultra-low dose Bevacizumab plus Temozolomide
Hebei Yanda Hospital; Hebei Yanda Hospital, Supported by Hebei Yanda Hospital
Recurrent High-grade Glioma
 
 
RSR-HCC-2019-001, NCT06261138: Survival Analysis: TACE vs. Combination Therapy in HCC

Completed
N/A
279
RoW
Transarterial chemoembolization, TACE, Systemic treatment
Zhejiang University
Hepatocellular Carcinoma
03/23
10/23
ChiCTR1800016652: Real-world data analysis of bevacizumab in patients with non-squamous non-small cell lung cancer Study Protocol

Not yet recruiting
N/A
1000
 
NA
Shanghai Chest Hospital, Shanghai Jiaotong University; Shanghai Chest Hospital, Shanghai Jiaotong University, Beijing Bethune Public Welfare Foundation
Non-small cell lung cancer
 
 
ChiCTR1900023502: Clinical effects and early assessment of high intensity focused ultrasound combined with bevacizumab in the treatment of colorectal liver metastases

Not yet recruiting
N/A
90
 
HIFU ;bevacizumab ;HIFU+bevacizumab
Huadong Hospital; Huadong Hospital, Huadong Hospital Project
colorectal cancer
 
 
ChiCTR-IOR-16009658: A precision medicine-based clinical study of screening targeted drug combined with chemotherapy for the treatment of primary advanced ovarian cancer

Not yet recruiting
N/A
400
 
Carboplatin+Paclitaxel ;Bevacizumab+Carboplatin+Paclitaxel ;Dosage according to the combination use of 3D bioprinting technology and dose recommended by the pharmacodynamics ;Dosage according to the recommended dose of international clinical trial phase III(GOG-0218)
Department of Gynecology and Obstetrics, Renji Hospital Affiliated to Shanghai JiaoTong University School of Medicine; Ren Ji Hospital Affiliated to Shanghai JiaoTong University School of Medicine, School of Medicine, Shanghai Jiao Tong University
Ovarian Cancer
 
 
NCT01993043: 39946-I Laser and Bevacizumab Treatment for Retinopathy of Prematurity

Completed
N/A
150
US
Baylor College of Medicine
ROP Threshold
10/20
09/23
ACTRN12624000463572: Randomised Clinical Trial: Influence of Subconjunctival Anaesthesia Duration on Pain Perception During Intravitreal Injections

Completed
N/A
240
 
Jiyeon Kim, Christchurch Public Hospital, Eye clinic
intravitreal injection pain, age-related macular degeneration, retinal vein occlusion, diabetic macular oedema
 
 
NCT06323382: Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

Recruiting
N/A
240
RoW
Locoregional therapy, TACE/HAIC, Bevacizumab, Atezolizumab, Tislelizumab, Toripalimab, Sintilimab, Camrelizumab
Sun Yat-sen University
Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab
12/24
12/24
ABCHCaen, NCT06416683: Atezolizumab and Bevacizumab Combination Recommended in a Multidisciplinary Consultation Meeting in Caen for Hepatocellular Carcinoma

Completed
N/A
109
Europe
University Hospital, Caen
Atezolizumab and Bevacizumab in Hepatocellular Carcinoma
06/23
01/24
NCT04446793: Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer

No Longer Available
N/A
NA
Onvansertib, Bevacizumab, FOLFIRI
Cardiff Oncology
Metastatic Colorectal Cancer, KRAS Gene Mutation
 
 
ChiCTR2100042595: Short Term and Sustained EyePressure Changes after Intraocular injection of Bevacizumab in Diabetic Retinopathy Patients

Completed
N/A
42
 
intravitreal bevacisumab
University of Health Sciences, Lahore, Pakistan; Gujranwala Medical College, Nil
Diabetic Retinopathy
 
 
NCT02354612: Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

No Longer Available
N/A
US
TRC105, Chimeric Antibody (TRC105) to CD105, Bevacizumab, Avastin, Axitinib, Inlyta, Pazopanib, Votrient, Capecitabine, Xeloda
Tracon Pharmaceuticals Inc.
Solid Tumors
 
 
NCT04601688: Branch Retinal Vein Occlusion (BRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.

Not yet recruiting
N/A
100
RoW
Bevacizumab Ophthalmic and Intravitreal Dexamethasone, Avastin®, Ozurdex®, Bevacizumab Ophthalmic
He Eye Hospital
Branch Retinal Vein Occlusion
03/21
09/21
NCT06199297: Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma

Completed
N/A
188
RoW
Atezolizumab combined with Bevacizumab, Sintilimab combined with Bevacizumab, Transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy
Sun Yat-sen University
Hepatocellular Carcinoma
07/23
07/23
NCT04601701: Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.

Recruiting
N/A
100
RoW
Bevacizumab Ophthalmic and Intravitreal Dexamethasone., Avastin®, Ozurdex®, Bevacizumab Ophthalmic.
He Eye Hospital
Central Retinal Vein Occlusion
03/21
09/21
NCT03286738: Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer

Recruiting
N/A
1800
RoW
FOLFIRI, target agent
Joong Bae Ahn
Metastatic Colorectal Cancer
12/21
12/21
NCT05080803: Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome

Completed
N/A
608
Europe
intravitreal administration of bevacizumab/ranibizumab/aflibercept/desamethazone
European School of Advanced Studies in Ophthalmology
Diabetic Macular Edema
12/21
07/22
ChiCTR2000034017: Study on the clinical benefits of reoperation in patients with recurrent glioblastoma

Not yet recruiting
N/A
180
 
Maximum range of brain tumor resection +/ chemotherapy (temozolomide/bevacizumab)+/ radiotherapy + adjuvant therapy ;Maximum range of brain tumor resection +adjuvant therapy ;Chemotherapy (temozolomide/bevacizumab)+/ radiotherapy + adjuvant therapy ;Chemotherapy (temozolomide/bevacizumab)+ adjuvant therapy
Zhongnan Hospital of Wuhan University; Zhongnan Hospital of Wuhan University, Investigator sponsored
Glioblastoma
 
 
BEST, NCT06039124: Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH

Completed
N/A
23
Europe
bevacizumab treatment
Hospices Civils de Lyon
Hemorrhagic Hereditary Telangiectasia, HHT
01/22
08/22
ChiCTR2000041205: Treating Leukoencephalopathy With Calcifications and Cysts With Bevacizumab

Completed
N/A
1
 
bevacizumab
The First Affiliated Hospital, School of Medicine, Zhejiang University; The First Affiliated Hospital, School of Medicine, Zhejiang University, Medical insurance and self-payment
Inherited Leukoencepalopathy
 
 
ASTRAL-HCC, UMIN000045131: An Exploratory Serum Cytokine Analysis of Atezolizumab + Bevacizumab Combination Therapy in Patients With Hepatocellular Carcinoma: A Multicenter Prospective Observational Study

Enrolling by invitation
N/A
20
Japan
Tecentriq (atezolizumab) - Roche, Avastin (bevacizumab) - Roche
National Center for Global Health and Medicine Hospital, National Center for Global Health and Medicine
Hepatocellular Carcinoma
 
 
NCT04684095: The Effect of ePRO on Quality of Life and Prognosis of Patients With Unresectable Metastatic Colorectal Cancer

Recruiting
N/A
338
RoW
electronic patient report outcome
Harbin Medical University
Colorectal Cancer Metastatic, Cancer
02/22
06/24
ChiCTR2100052354: Real world study on safety and economic evaluation of bevacizumab quality system

Not yet recruiting
N/A
200
 
No
The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Supported by Shanghai Aisha Medical Technology Co., Ltd
rectal cancer
 
 
ROBOT, NCT04213222: Radiomics Assess of Bevacizumab Plus Chemo in Colorectal Cancer Liver Metastases

Not yet recruiting
N/A
300
RoW
Bevacizumab
Peking University People's Hospital
Colon Cancer, Rectal Cancer, Liver Metastases
06/22
12/23
ChiCTR2200061793: Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: a preliminary multicenter single-arm prospective study

Completed
N/A
30
 
None
The Third Affiliated Hospital of the Third Affiliated Hospital of the Naval Medical University; The Third Affiliated Hospital of the Third Affiliated Hospital of the Naval Medical University, Self-raised
hepatocellular carcinoma complicated with portal vein tumor thrombus
 
 
AIR:RRP, NCT03465280: Airway Intervention Registry (AIR): Recurrent Respiratory Papillomatosis (RRP)

Recruiting
N/A
400
Europe
Microdebrider, Cold-steel surgery (forceps), Carbon dioxide laser, Potassium titanyl phosphate (KTP) laser, Pulsed dye laser, Radiofrequency ablation, Monopolar suction diathermy, Plasma coagulation, Other, Adjuvant therapies, Acyclovir, Artemisinin, Bevacizumab (Avastin), Celecoxib (Celebrex), Cidofovir, Cimetidine, Di-indolmethane (DIM), Gardasil, Indole-3-carbinol (I3C), alpha-Interferon, PEG-Interferon, Methotrexate, Retinoic acid (isotretinoin), Ribavarin
Newcastle-upon-Tyne Hospitals NHS Trust, Alder Hey Children's NHS Foundation Trust, National Institute for Health Research, United Kingdom
Recurrent Respiratory Papillomatosis, Human Papilloma Virus
08/22
08/22
COBRA, NCT03451370: First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer

Active, not recruiting
N/A
121
Europe
Capecitabine, Oxaliplatin, Bevacizumab
Istituto Oncologico Veneto IRCCS
Elderly Metastatic Colorectal Cancer Patients
07/24
12/24
EVA DOPA, NCT04566185: Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma

Recruiting
N/A
30
Europe
FDG PET, CT scan, Magnetic resonance imaging (MRI)
Centre Hospitalier Universitaire de Nīmes
Glioblastoma
09/22
09/22
NCT05544812: A Small-sample, Real-world Study of Sintilimab Plus Bevacizumab/Cetuximab Plus XELOX Regimen for Conversion Therapy in Patients With Advanced Colorectal Cancer

Recruiting
N/A
10
RoW
Sintilimab ,bevcizumab/cetuximab,XELOX
Xijing Hospital
Colorectal Cancer
09/22
06/23
NCT04446416: Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients

Completed
N/A
6
RoW
NaviFUS System, Bevacizumab, Avastin
NaviFUS Corporation, Chang Gung Memorial Hospital
Glioblastoma Multiforme, Glioblastoma, Glioma, Brain Tumor, Neoplasms, Neoplasms, Nerve Tissue
09/22
08/23
ChiCTR2000036117: Study on the diagnosis and treatment strategy of neurofibromatosis type 2 based on evidence-based medicine

Not yet recruiting
N/A
80
 
Cochlear implant ;Treatment of Avastin ;follow-up observation
Ninth Perople's Hospital, Shanghai Jiao Tong University School of Medicine; Hospital Development Center, Hospital Development Center
Neurofibromatosis type 2
 
 
NCT06031376: Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC

Completed
N/A
106
RoW
Fruquintinib, PD-1 inhibitors, anti-PD-1 antibodies, Trifluridine/Tipiracil, TAS-102, Lonsurf, S 95005, Bevacizumab, Avastin
Hunan Cancer Hospital
Metastatic Colorectal Adenocarcinoma
10/22
03/23
NCT05869097: Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer

Completed
N/A
90
RoW
Trifluridine/Tipiracil, TAS-102, Lonsurf, S 95005, Bevacizumab, Avastin
Hunan Cancer Hospital
Metastatic Colorectal Adenocarcinoma
10/22
04/23
RANT, NCT05277675: Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma ( Study)

Recruiting
N/A
160
RoW
Tislelizumab/Sintilimab+Lenvatinib/Bevacizumab, RFA
Southwest Hospital, China
Hepatocellular Carcinoma Recurrent
11/22
10/23
ChiCTR2000040267: A prospective, single-arm, single-center clinical study of anlotinib hydrochloride for maintenance treatment of patients with advanced non-small cell lung cancer after chemotherapy combined with bevacizumab as first-line treatment

Not yet recruiting
N/A
30
 
Oral Anlotinib 12mg/qd, Stop using for one week after two consecutive weeks,Q3W, until disease progression
Xingtai People's Hospital; Xingtai People's Hospital, self-financing
Non-small cell lung cancer
 
 
ChiCTR1900027023: A non-inferiority study of apatinib versus bevacizumab combined with XELOX regimen in the treatment of metastatic colorectal cancer

Recruiting
N/A
120
 
Apatinib 250mg po, qd, continuous taken; XELOX: Oxaliplatin 135 mg/m2 Ivgtt d1, Capecitabine 1000mg/m2 d1-14, q3w ;Bevacizumab 7.5mg/kg, q3w; XELOX: Oxaliplatin 135 mg/m2 Ivgtt d1, Capecitabine 1000mg/m2 d1-14, q3w
Tangshan People's Hospital; Tangshan people's Hospital, self-raise
colorectal cancer
 
 
ChiCTR2000031722: A non-interventional, single-arm, prospective clinical study for the efficacy and safety of gefitinib combined with bevacizumab and pemetrexed in first-line treatment of stage IV EGFR mutant non-squamous non-small cell lung cancer.

Recruiting
N/A
200
 
gefitinib, bevacizumab and pemetrexed
Shandong Cancer Hospital; Shandong Cancer Hospital, Self-finance
Lung Cancer
 
 
ChiCTR2000036551: Establishment and validation of therapeutic effect prediction model of first line treatment of bevacizumab combined with mFOLFOX6 in Ras mutant colorectal cancer patients with liver metastasis

Not yet recruiting
N/A
 
Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, Shanghai Shenkang Hospital Development Center
colorectal cancer
 
 
NCT04862949: Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

Completed
N/A
124
RoW
Atezolizumab plus bevacizumab
CHA University, Hoffmann-La Roche
Advanced Hepatocellular Carcinoma
12/22
03/23
NCT06023173: Deep Radiomics-based Fusion Model Predicting Bevacizumab Treatment Response and Outcome in Patients With Colorectal Liver Metastases

Completed
N/A
307
RoW
Deep radiomics-based fusion model, deep learning model
Fudan University
The Patients With CRLM Who Benefit More From Bevacizumab
01/23
01/23
IBIZA-1, NCT05498051 / 2021-006700-32: Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Submucosal Bevacizumab-800CW.

Completed
N/A
5
Europe
Sentinel lymph node identification, SLN
Meander Medical Center, Meander Medisch Centrum
Colonic Neoplasms, Sentinel Lymph Node, Fluorescence, Colorectal Neoplasms
02/23
06/23
ChiCTR2200064495: Association Analysis of VEGF Inhibitors with Vascular Calcification: A Retrospective Study of Patients with Colorectal or Renal Cancer Treated with Bevacizumab

Not yet recruiting
N/A
 
none
Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Self-funded
Vascular Calcification Occurs in Patients with Colorectal or Kidney Cancer
 
 
ChiCTR2100051286: The efficacy and safety of Yadanzi oil injection in the treatment of advanced colon cancer

Recruiting
N/A
60
 
Basic chemotherapy + Bevacizumab + Yadanzi oil injection ;Basic chemotherapy + Bevacizumab
Shanxi Provincial Hospital of Traditional Chinese Medicine; Shanxi Provincial Hospital of Traditional Chinese Medicine, Department of Oncology, Shanxi Provincial Hospital of Traditional Chinese Medicine
advanced colon cancer
 
 
BELLA, NCT04575415: Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study

Recruiting
N/A
272
RoW
Bevacizumab, Avastin, Erlotinib, Tarceva, Gefitinib, Iressa, Icotinib, Conmana, Afatinib, Gilotrif, Dacomitinib, Vizimpro, Osimertinib, Tagrisso
Guangdong Association of Clinical Trials
NSCLC
05/23
12/23
NCT05410938: Intraperitoneal Chemotherapy Versus Triweekly Chemotherapy

Completed
N/A
59
RoW
Chemotherapy
Far Eastern Memorial Hospital
Intraperitoneal Chemotherapy, Bevacizumab, Ovarian Cancer
05/23
05/23
BETTER, NCT05407155: Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer

Not yet recruiting
N/A
56
NA
bevacizumab plus nab-paclitaxel and platinum
Fudan University
Non-small Cell Lung Cancer Metastatic
06/23
06/24
NCT06119347: Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors

Completed
N/A
1581
RoW
AntiVEGF, ICIs
First Affiliated Hospital of Wenzhou Medical University
AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs
06/23
10/23
ChiCTR2200055514: Effect of half-dose BYVASDA versus standard dose Avastin combined with mFOLFOX6 chemotherapy on metastatic colorectal cancer : A multicenter, open-label, parallel, randomized controlled clinical study

Recruiting
N/A
571
 
mFOLFOX6 +half-dose Bevacizumab (BYVASDA) ;mFOLFOX6 + half-dose Bevacizumab (Avastin)
Sichuan Cancer Hospital; Sichuan Cancer Hospital, self-financing and corporate sponsorship
metastatic colorectal cancer
 
 
NCT05703750: Impact of Clinical Evident Portal Hypertension on HCC With TACE (CHANCE-CHESS 2301)

Recruiting
N/A
228
RoW
TACE ± Systemic therapy
Zhongda Hospital
Hepatocellular Carcinoma, Portal Hypertension
06/23
12/23
NCT05704192: CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302)

Recruiting
N/A
373
RoW
TACE ± Systemic therapy
Zhongda Hospital
Hepatocellular Carcinoma, Portal Hypertension
06/23
12/23
ORCHESTRA, NCT01792934: Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases

Recruiting
N/A
478
Europe
XELOX regimen according to standard procedures, FOLFOX regimen according to standard procedures, Surgery, radiofrequency ablation (RFA), transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE), stereotactic body radiation therapy (SBRT), Bevacizumab, tumor biopsy
Radboud University Medical Center, Erasmus Medical Center
Multi-organ Metastatic Colorectal Cancer
07/23
07/25
NCT03648814: Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT

Recruiting
N/A
70
RoW
Intracameral injection, Intravitreal injection
Prince of Songkla University
Glaucoma, Neovascular, Vascular Endothelial Growth Factor Overexpression
07/23
07/23
ChiCTR2200061510: Clinical data analysis of bevacizumab-induced hypertension in patients with colorectal cancer

Completed
N/A
1054
 
None
The Sixth Affiliated Hospital of Sun Yat-Sen University; The Sixth Affiliated Hospital of Sun Yat-Sen University, Self-funded
Colorectal cancer
 
 
ChiCTR2000034451: Bevacizumab combined with afatinib for first-line treatment of locally advanced or advanced EGFR mutation-positive NSCLC patients: the effectiveness and safety database management platform construction project

Not yet recruiting
N/A
50
 
afatinib combined with bevacizumab
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Association of Oncology
NSCLC
 
 
IBIZA-2, NCT05497726 / 2021-006796-41: Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Intravenous Bevacizumab-800CW

Completed
N/A
5
Europe
Sentinel lymph node detection using intravenous bevacizumab-800CW
Meander Medical Center, Meander Medisch Centrum
Colorectal Neoplasms, Colon Neoplasm, Sentinel Lymph Node, Fluorescence
07/23
10/23
NCT05781633: The Efficacy and Safety of Eutideron, Etoposide, and Bevacizumab in Patients With Brain Metastases From Breast Cancer.

Recruiting
N/A
43
RoW
eutidrone etoposide bevacizumab
Tianjin Medical University Cancer Institute and Hospital
Mammary Neoplasms, Human
07/23
07/25
CHANCE2201, NCT05332821: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC

Recruiting
N/A
474
RoW
PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE
Zhongda Hospital
Hepatocellular Carcinoma
08/23
08/23
NCT03647592: Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer

Recruiting
N/A
30
RoW
Erlotinib/Gefitinib combined with Bevacizumab, treatment of A+T
Hunan Province Tumor Hospital
Non Small Cell Lung Cancer
08/24
12/25
CHANCE2202, NCT05332496: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC

Recruiting
N/A
220
RoW
PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE
Zhongda Hospital
Hepatocellular Carcinoma
08/23
09/23
ChiCTR2100050957: A multi-cohort real-world study of the efficacy and safety of bevacizumab in advanced recurrent ovarian cancer

Recruiting
N/A
200
 
6 cycles of bevacizumab IBI305 combined with platinum-containing doublet chemotherapy followed by 16 cycles of bevacizumab IBI305 maintenance therapy ;Bevacizumab in combination with non-platinum chemotherapy
The Second People's Hospital of Anhui Province; The Second People's Hospital of Anhui Province, self-funded
Advanced recurrent ovarian cancer
 
 
ChiCTR2100050106: An exploratory clinical study of fluzoparib combined with bevacizumab in the maintenance treatment of RAS mutant colorectal cancer after first-line chemotherapy

Not yet recruiting
N/A
30
 
fluzoparib combined with bevacizumab
Shanghai Dongfang Hospital; Shanghai Dongfang Hospital, Expenditure of department
RAS mutant colorectal cancer
 
 
SCENIC, NCT06292286: Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer

Recruiting
N/A
18
RoW
Carboplatin or cisplatin, Paraplatin or Platinol, Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar, Taxol, Gemzar, Caelyx, Bevacizumab or biosimilar, Avastin or mvasi, Cytoreductive surgery
The University of Hong Kong
Recurrent Ovarian Carcinoma
12/25
07/26
ChiCTR2100043740: Clinical observation of Ascending Lucidity Descending Turbidity Decoction combined with bevacizumab intracavitary injection in the treatment of malignant serous cavities effusion

Recruiting
N/A
60
 
ascending lucidity descending turbidity decoction orally ;bevacizumab intracavitary injection
Shenzhen Hospital of Beijing University of Traditional Chinese Medicine (Longgang); Shenzhen Hospital of Beijing University of traditional Chinese medicine (Longgang), Project funds of 'Yulong talent' training plan in 2020
Malignant serous cavity effusion
 
 
NCT04770376: Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 and Endothelial Internal Tunica Cell Kinase 2 in Patients With Ovarian Cancer Treated With Chemotherapy Associated to Bevacizumab

Recruiting
N/A
150
Europe
Observational study. Blood samples will be collected at scheduled blood draws performed as per clinical practice before each cycle of chemotherapy.
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Ospedale SS Giovanni e Paolo, Venezia
Ovarian Cancer
12/23
12/23
CHANCE023, NCT06024252: Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study

Not yet recruiting
N/A
200
NA
TACE, Atezolizumab, Bevacizumab
Zhongda Hospital
HCC
12/23
06/24
LenBev-001, NCT06435013: Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCC

Completed
N/A
208
RoW
Lenvatinib
Sun Yat-sen University
Hepatocellular Carcinoma, Lenvatinib
03/24
05/24
ChiCTR2000037472: An open labeled, randomized controlled phase II pilot trial of systematic treatment with or without SBRT in the management of gynecologic cancer with first line chemotherapy induced oligo metastasis

Not yet recruiting
N/A
120
 
paclitaxel plus cisplatin or carboplatin with or without Bevacizumab ;paclitaxel plus cisplatin or carboplatin + PD-1 checkpoint inhibitor with or without Bevacizumab ;paclitaxel plus cisplatin or carboplatin with or without Bevacizumab, combined oligo-metastasis SBRT ;paclitaxel plus cisplatin or carboplatin+PD-1 checkpoint inhibitor with or without Bevacizumab, combined oligo-metastasis SBRT
Shanghai First Maternity and Infant Hospital; Shanghai First Maternity and Infant Hospital, Shanghai Hospital Development Center
Gyenecological cancer
 
 
ChiCTR2000037649: Hypofractionated Stereotactic Radiotherapy With PD-L1 Inhibitor and Bevacizumab in Patients With Recurrent High-Grade Gliomas: a Prospective Single Center Exploratory Clinical Trial

Not yet recruiting
N/A
32
China
Hypofractionated Stereotactic Radiotherapy + Durvalumab+ Bevacizumab
Huashan Hospital, Fudan University ; Huashan Hospital, Fudan University, Huashan Hospital, Fudan University
High-Grade Glioma
 
 
ChiCTR2100043395: Gefitinib plus pemetrexed combined with bevacizumab or carboplatin in first-line treatment of stage IV EGFR mutant non-squamous non-small cell lung cancer.

Recruiting
N/A
309
 
Gefitinib plus pemetrexed and bevacizumab ;Gefitinib plus pemetrexed and carboplatin
Shandong Cancer Hospital; 440 Jiyan Street, Huaiyin District, Self-finance
Lung Cancer
 
 
ChiCTR2100045399: TCM evidence-based capacity building and evidence-based implementation plan of TCM combined with chemotherapy in treatment of metastatic colorectal cancer:A bidirectional cohort study of Zhenqiliujun anti-cancer granules combined with mFOLFOX6/FOLFIRI regimen and bevacizumab/cetuximab in first-line treatment of advanced metastatic colorectal

Recruiting
N/A
362
 
MFOLFOX6 /FOLFIRI regimen + bevacizumab/cetuximab + Zhenqi Liujun cancer suppressant granules. ;MFOLFOX6 /FOLFIRI + bevacizumab/cetuximab
Department of Oncology, Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University; The Traditional Chinese Medicine Hospital Affiliated to Southwest, National Administration ofnTraditional Chinese Medicine
colorectal cancer
 
 
ChiCTR2100046780: Post marketing safety and economic evaluation of bevacizumab injection

Recruiting
N/A
3100
 
None ;None ;None ;None
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wu Jieping Medical Foundation
Non small cell lung cancer
 
 
NCT05173298: Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Recruiting
N/A
100
RoW
atezolizumab plus bevacizumab
CHA University, Boryung Pharmaceutical Co., Ltd
Advanced Hepatocellular Carcinoma
07/24
12/24
TACE-TKI-ICI, NCT05717738: Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

Recruiting
N/A
300
RoW
TACE, transarterial chemoembolization, Lenvatinib, levima, Anti-PD-1 monoclonal antibody, PD-1 inhibitor, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, apatinib plus camrelizumab, Apa plus C, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga
Tongji Hospital, Chinese Cooperative Group of Liver Cancer, Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, The Second Affiliated Hospital of Fujian Medical University, Geneplus-Beijing Co. Ltd., Haplox Biotechnology Co., Ltd.
Hepatocellular Carcinoma Non-resectable
12/23
12/24
STAR-T, NCT05839951: An Observational Study Called to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions

Active, not recruiting
N/A
818
US
Regorafenib (BAY73-4506, Stivarga®), TAS-102 (trifluridine and tipiracil, Lonsurf®), Bevacizumab
Bayer
Metastatic Colorectal Cancer (mCRC)
10/24
10/24
ZG005-IIT-001, NCT06233994: A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Not yet recruiting
N/A
30
RoW
ZG005 Powder for Injection, ZG005, Donafenib Tosilate Tablets, Donafenib, Bevacizumab
Changsha Taihe Hospital
Advanced Hepatocellular Carcinoma
01/26
01/26
DEBIRI, NCT06177288: Combined With Chemotherapy and Bevacizumab in the Treatment of Unresectable Colorectal Cancer Liver Metastases

Not yet recruiting
N/A
39
RoW
DEBIRI Combined With Chemotherapy and Bevacizumab
Fudan University
Colorectal Neoplasms
01/25
05/25
NCT06265350: Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases

Recruiting
N/A
80
RoW
Cadonilimab, Bevacizumab, Cryoablation
Sun Yat-sen University
Hepatocellular Carcinoma, Liver Cancer Stage IV, Pulmonary Metastases, Cadonilimab, Bevacizumab, Cryoablation
01/26
01/27
NCT06244446: Efficacy and Safety of SBRT Combined With Atezolizumab Plus Bevacizumab vs Atezolizumab Plus Bevacizumab in Treating Unresectable Advance Hepatocellular Carcinoma.

Not yet recruiting
N/A
40
RoW
No intervention
Institute of Liver and Biliary Sciences, India
Advanced Hepatocellular Carcinoma
01/25
01/25
ChiCTR2200055254: Exploratory study on the efficacy of utidelone combined with capecitabine and bevacizumab in the treatment of brain metastasis of HER2 negative breast cancer

Recruiting
N/A
29
 
utidelone combined with capecitabine and bevacizumab
Huashan Hospital Affiliated to Fudan University; Huashan Hospital Affiliated to Fudan University, Beijing Heath Medical Oncology Research Foundation
breast cancer
 
 
ChiCTR2200057280: Efficacy and safety of low-dose afatinib combined with bevacizumab and pemetrexate in first-line treatment of stage IV lung adenocarcinoma with EGFR mutation

Recruiting
N/A
100
 
low-dose alfaatinib combined with bevacizumab and pemetrexed
Shandong Cancer Hospital; Shandong Cancer Hospital, self-funded
Lung Cancer
 
 
ATTRACT, NCT04944069: Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis

Not yet recruiting
N/A
69
RoW
Almonertinib, Bevacizumab
Second Affiliated Hospital of Nanchang University, Jiangsu Hansoh Pharmaceutical Co., Ltd.
NSCLC, Leptomeningeal Metastasis, EGFR Activating Mutation
03/24
03/25
MARGIN-2, NCT05939310: Fluorescence Guided Surgery in Breast Cancer - The Study

Recruiting
N/A
70
Europe
Fluorescence guided detection of tumor positive margins.
University Medical Center Groningen, Martini Hospital Groningen
Breast Cancer, Breast Cancer Invasive
09/24
12/24
NCT06349044: A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Recruiting
N/A
120
RoW
Hypofractionated radiotherapy/SBRT(5-10Gy/fx,3-5 fx), Anti-PD-1 monoclonal antibody, Oxaliplatin and Capecitabine, Anti-VEGF 15mg/kg, Anti-VEGF 7.5mg/kg, Gemcitabine and Cisplatin
Zhejiang Cancer Hospital
Her-2 Negative Adenocarcinoma of the Gastro-oesophageal Junction/Gastric Adenocarcinoma, Hepatocellular Carcinoma, Biliary Tract Carcinoma, Colorectal Adenocarcinoma
12/25
12/25
NCT05211804: Mechanisms of Retinal Revascularization and Clinical Indicators of Neovascular AMD Relapse

Completed
N/A
31
Europe
Ophthalmic Drugs, Aflibercept, Bevacizumab, Ranibizumab
Sorlandet Hospital HF
Wet Macular Degeneration
05/24
05/24
NCT03698162: Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases

Terminated
N/A
14
US
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, DCE MRI, DCE-MRI, DYNAMIC CONTRAST ENHANCED MRI, Bevacizumab Injection, Avastin
University of Southern California, National Cancer Institute (NCI)
Brain Metastases, Glioma of Brain, Brain Tumor, Metastatic Melanoma
11/23
11/23
 

Download Options